The effect of infection with Toxoplasma gondii in inducing interferon-gamma in breast cancer patients

Document Type : Original Articles

Authors

Department of Microbiology, College of Medicine, University of Thi-qar, Thi-qar, Iraq

10.32592/ARI.2024.79.1.138

Abstract

Toxoplasmosis is among the most pervasive zoonotic illnesses in the world. Human infection rates range from 10% to 80% in many countries. Cancer patients receiving chemotherapy are more susceptible to developing acute forms of toxoplasmosis, which can cause brain defects, neurological damage, and encephalitis. The present study aimed to evaluate the effect of infection with Toxoplasma gondii in inducing interferon-gamma in breast cancer patients from Iraq. This cross-sectional descriptive work was carried out on women who were suffering from breast cancer referring to Al-Haboubi Teaching Hospital in Nasiriya City-Thi-Qar province (Iraq) during the period extended from January to September 2022. About 3 mL of blood was obtained from all participants and sera were collected. Sera were then tested using the enzyme-linked immunosorbent assay (ELISA) kits of Toxoplasma IgM, IgG, and IFN-γ (Nova Tec Immunodiagnostica GmbH, Germany) according to the manufacturer’s protocols. Before blood collection, a printed questionnaire with some demographical information, e.g., age and residence, was completed for participants. The total number of positive patients for T. gondii infection from breast cancer patients in the current study was 60 (85.7%). The results of the analyzing specimens by ELISA test revealed that 85.7% and 74.2% of the patients were positive for IgG and IgM, respectively. The mean level of IFN-γ in breast cancer patients with toxoplasmosis, without toxoplasmosis, and control group was 47.66, 0.00, and 0.57 pg/mL, respectively. Higher IgG and interferon-gamma levels were found in the group of breast cancer patients with toxoplasmosis compared to the group without. According to the ELISA findings, T. gondii was the most common parasite among cancer patients.

Keywords

References

References
1. Robert-Gangneux F, Dardé ML. Epidemiology of and
diagnostic strategies for toxoplasmosis. Clinical microbiology
reviews. 2012;25(2):264-96.
2. Mehrabi F, Rassouli M, Chashmi SH. Molecular Detection of
Toxoplasma gondii in Chicken Meats and Eggs in Semnan
City, Iran. Iranian Journal of Veterinary Medicine.
2023;17(2):167-72.
3. Saadatmand M, Al-Awsi GR, Alanazi AD, Sepahvand A,
Shakibaie M, Shojaee S, Mohammadi R, Mahmoudvand H.
Green synthesis of zinc nanoparticles using Lavandula
angustifolia Vera. Extract by microwave method and its
prophylactic effects on Toxoplasma gondii infection. Saudi
Journal of Biological Sciences. 2021;28(11):6454-60.
4. Denkers EY, Gazzinelli RT. Regulation and function of Tcell-mediated immunity during Toxoplasma gondii infection.
Clinical microbiology reviews. 1998;11(4):569-88.
5. Ali Anvar SA, Nowruzi B, Afshari G. A Review of the
Application of Nanoparticles Biosynthesized by Microalgae
and Cyanobacteria in Medical and Veterinary Sciences.
Iranian Journal of Veterinary Medicine. 2023 Jan 1;17(1).
6. Cheraghipour K, Masoori L, Ezzatkhah F, Salimikia I, Amiri
S, Makenali AS, Taherpour F, Mahmoudvand H. Effect of
chitosan on Toxoplasma gondii infection: A systematic
review. Parasite epidemiology and control. 2020;11:e00189.
7. Cheraghipour K, Masoori L, Ezzatpour B, Roozbehani M,
Sheikhian A, Malekara V, Niazi M, Mardanshah O,
Moradpour K, Mahmoudvand H. The experimental role of
medicinal plants in treatment of Toxoplasma gondii infection:
a systematic review. Acta parasitologica. 2021;66:303-28.
8. Olfaty-Harsini S, Shokrani H, Nayebzadeh H. Toxoplasma
gondii infection in salaughtered ewes in Khorram-abad,
western Iran: A preliminary molecular study. Iran J Vet Med.
2017;11(3).
9. Anvari D, Sharif M, Sarvi S, Aghayan SA, Gholami S,
Pagheh AS, Hosseini SA, Saberi R, Chegeni TN,
Hosseininejad Z, Daryani A. Seroprevalence of Toxoplasma
gondii infection in cancer patients: a systematic review and
meta-analysis. Microbial pathogenesis. 2019;129:30-42.
10. Tao Z, Shi A, Lu C, Song T, Zhang Z, Zhao J. Breast cancer:
epidemiology and etiology. Cell biochemistry and biophysics.
2015;72:333-8.
11. Wang L, He LY, Meng DD, Chen ZW, Wen H, Fang GS,
Luo QL, Huang KQ, Shen JL. Seroprevalence and genetic
characterization of Toxoplasma gondii in cancer patients in
148 Azab Hameed et al / Archives of Razi Institute, Vol. 79, No. 1 (2024) 143-148
Anhui Province, Eastern China. Parasites & vectors.
2015;8(1):1-7.
12. Pradhan S, Yadav R, Mishra VN. Toxoplasma
meningoencephalitis in HIV-seronegative patients: clinical
patterns, imaging features and treatment outcome.
Transactions of the Royal Society of Tropical Medicine and
Hygiene. 2007;101(1):25-33.
13. Ahmed DF, Saheb EJ. Prevalence of Toxoplasmosis
Infection in Iraqi Women with Different Types of Cancer.
Diyala Journal of Medicine. 2017;13(2):56-62.
14. Al-Muskakeh MK, Yaseen AN, Aldabagh MA. Assessment
of Soluble PD-1 and PD-L1 in Iraqi Women Patients with
Breast Cancer with Toxoplasmosis. Indian Journal of Forensic
Medicine & Toxicology. 2022;16(1).
15. Al-Tameemi IA, Abdullah BH, Raisan SJ. Seroprevalence
of T. gondii among cancer patients in Basrah provinc, Iraq.
2018;8(1):193-199. DOI:10.20959/wjpr20191-13808.
16. Ali MI, Abd El Wahab WM, Hamdy DA, Hassan A.
Toxoplasma gondii in cancer patients receiving chemotherapy:
seroprevalence and interferon gamma level. Journal of
Parasitic Diseases. 2019;43(3): 464-471.
17. Imam A, Al-Anzi FG, Al-Ghasham MA, Al-Suraikh MA,
Al-Yahya AO, Rasheed Z. Serologic evidence of Toxoplasma
gondii infection among cancer patients. A prospective study
from Qassim region, Saudi Arabia. Saudi medical journal.
2017;38(3):319.
18. Assim MM, Saheb EJ. The Association of Severe
Toxoplasmosis and Some Cytokine Levels in Breast Cancer
Patients. Iraqi Journal of Science. 2018:1189-94.
19. Sasai M, Pradipta A, Yamamoto M. Host immune responses
to Toxoplasma gondii. International Immunology.
2018;30(3):113-9.
20. Sturge CR, Yarovinsky F. Complex immune cell interplay in
the gamma interferon response during Toxoplasma gondii
infection. Infection and immunity. 2014;82(8):3090-7.
21. Suzuki Y, Sa Q, Gehman M, Ochiai E. Interferon-gammaand perforin-mediated immune responses for resistance
against Toxoplasma gondii in the brain. Expert reviews in
molecular medicine. 2011;13:e31.
22. Abdul-Lateef HI, AL-Najar SA, Majeed NG. The levels of
IFN-, IL-12 And testosterone hormone in persons with
asymptomatic toxoplasmosis. Journal of the Faculty of
Medicine Baghdad. 2012;54(1):79-82.
23. Alomashi GB, Al-Kilabi AJ. Association of IL-17 and IFNg in Patients of Breast Cancer Infected and non-Infected with
Toxoplasmosis. Annals of the Romanian Society for Cell
Biology. 2021:11172-81.
24. Caras I, Grigorescu A, Stavaru C, Radu DL, Mogos I, Szegli
G, Salageanu A. Evidence for immune defects in breast and
lung cancer patients. Cancer Immunology, Immunotherapy.
2004;53:1146-52.
25. Hassan NE, Mohammed AA. Determination of Interferon
Gamma Protein in Serum of Breast Cancer Patients Using the
ELISA. Journal of Applied Sciences and Nanotechnology.
2021;2(1):37-48.
Archives of Razi Institute
Volume 79, Issue 1
January and February 2024
Pages 138-143

Files

Share

How to cite

Statistics